Chairs
- Robert L. Coleman (The Woodlands, TX, United States of America)
- Susana Banerjee (London, United Kingdom)
Why are we having this Symposium? Recent regulatory actions by FDA/EMEA regarding late-stage approval for PARPi in recurrent ovarian cancer
Speakers
- Robert L. Coleman (The Woodlands, TX, United States of America)
Is there clinical evidence to support the link between PARPi use and a negative impact on OS?
Speakers
- Jonathan A. Ledermann (London, London, United Kingdom)
Is there a biological rationale to support decremental impact on overall survival?
Speakers
- Antonio Jose Gonzalez Martin (Madrid, Spain)
What is the impact of overall survival results of PARP inhibitor trials?
Speakers
- Susana Banerjee (London, United Kingdom)